ACMG says the NIH program will dramatically improve understanding of the clinical implications of genetic variation and its role in improving patient and population health.
Qiagen’s Clinical Insight bioinformatics offering enables clinical labs to interpret and report genomic variants.
Seegene’s Allplex GI panel covers 25 bacterial, viral, and parasitic causes of gastrointestinal infectious disease.
The Aquios CL flow cytometer is a fully automated instrument that delivers first results within 20 minutes.
The GeneStrat test by Biodesix reveals actionable NSCLC mutations, returning results within 72 hours.
Software designed to assist pathologists through the process of infant autopsies can save time, make reference materials easily accessible, and improve the quality of perinatal autopsy reports.
With CLIA-waived status, Roche’s Cobas Strep A test is now available for use in physician offices and retail clinics.
Phase I SBIR grant for sickle cell disease research supported by scientific data recently published in Pediatric Blood & Cancer.
A new molecular PCR test identifies KRAS mutations to aid in determining therapy for metastatic colorectal cancer.
Participating insurers now include Anthem Blue Cross and Blue Shield, which has more than 37 million members across 14 states, and CareFirst BlueCross BlueShield PPO, with 2.3 million eligible members across Maryland, northern Virginia, and Washington, DC.
A new screening method may detect twice as many women with ovarian cancer as conventional strategies, according to results from the largest trial of its kind, led by researchers at University College London.
Research recently published in Clinical Biochemistry identifies the precise magnitude of change in cardiac troponin required for early diagnosis of myocardial infarction.
Spanning from clinical diagnostics to business strategy, this year’s expanded program encompasses predictive cancer biomarkers, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, cell-free DNA, commercialization, cancer immunotherapy, and reimbursement.
The 10-year agreement extends a decades-long manufacturing and supply partnership in immunodiagnostic testing for blood viruses and infectious diseases.
Noninvasive liquid biopsy enables detection of emerging T790M mutations with greater sensitivity than tissue biopsy and months before detection of cancer progression with imaging.
Abbott’s first-of-its-kind blood test to aid in detecting early pregnancy could help doctors make faster treatment decisions for women.
As China sees a rise in birth rates, a genetic screening processor and neonatal reagent kit delivers advanced capabilities to newborn screening labs for detecting life-threatening conditions.
ESCMID warns that Europe may surpass one million deaths due to ineffective antibiotics by 2025.
CE marked and assigned to moderate complexity status in the United States, the Simplexa PCR-based strep A direct test by Focus Diagnostics is now available internationally.
Studies led by Mayo Clinic investigators combine common genetic variants and other factors to improve personalized estimates of breast cancer risk.